Redeye: Faron Pharmaceuticals H1 - Turbulent times behind, promising times ahead
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H1 report. With upcoming BEXMAB read-outs, a planned pivotal study and a potential license deal on the horizon, we see promising times ahead for the company. Following the company’s recent clinical progression, positive FDA feedback and a granted Fast Track Designation, we increase our base case valuation to EUR2.8 (2) per share.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/